Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Azacytidine vs Daunorubicin + Cytarabine in Adult AML with Adverse Risk Features
NCT05939180Phase 3Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Apr 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of venetoclax in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Started Apr 2024; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05939180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05939180.